

National Cancer Advisory Board

Ad Hoc Subcommittee on Experimental Therapeutics

The purpose of this subcommittee is to provide advice and guidance on issues related to developing cancer-relevant agents in keeping with the National Cancer Act and the National Cancer Plan.

This includes the translation to the clinic of novel anticancer therapeutic interventions either synthetic, natural product, small molecule, vaccine, cell therapy, biologic, or other therapeutic. The subcommittee should also encourage greater interactions with industry, academia, government, NIH intramural programs, etc., to enhance the drug development process, with an eye to bridging gaps between discovery and clinical testing.

This subcommittee will also provide advice on policies, procedures, and programs that will enhance the pre-clinical discovery and development of small molecules and biologics, as well as biomarkers and diagnostics that fall under the category of experimental therapeutics.

The subcommittee shall further provide review of the NCI Experimental Therapeutics Program (NExT), the Division of Cancer Treatment and Diagnosis (DCTD) drug development efforts, the drug development efforts of the Experimental Therapeutics Clinical Trials Network (ETCTN), and other extramural division activities related to experimental therapeutics. The goal is to optimize the functionality, quality, and output of these programs, accelerate innovations, and foster collaboration and cross-fertilization with communities served across the cancer research community including basic science investigators, the network of comprehensive cancer centers, and agencies such as the FDA as well as the pharmaceutical industry. The subcommittee will additionally provide input regarding educational measures to ensure balanced workforce, stewardship of government funding, and potential contribution of current and future drug discovery and development practices.

It is expected that the subcommittee may request information towards evaluating any aspect of the NCI funded experimental therapeutics research portfolio. An annual report will be provided to the NCAB. The subcommittee, in conjunction with the NCAB, shall review the mission statement every 5 years. At that time, the NCAB shall ascertain the need to retain the subcommittee.

Members:

Dr. Richard Boxer - Chair
Dr. Nilofer Azad
Dr. Callisia Clarke
Dr. Luis Diaz
Ms. Julie Grant
Dr. Andrea Hayes Dixon
Dr. Amy Heimberger
Dr. Ashani Weeraratna

Executive Secretary:

Dr. Rose Aurigemma
(240) 276-5465